Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen G. Wei, Vicki Chiang, Elizabeth Fyne, et al.
PLoS Pathogens (2014) Vol. 10, Iss. 4, pp. e1004071-e1004071
Open Access | Times Cited: 268

Showing 1-25 of 268 citing articles:

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen, Martin Tolstrup, Christel R. Brinkmann, et al.
The Lancet HIV (2014) Vol. 1, Iss. 1, pp. e13-e21
Closed Access | Times Cited: 584
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H Elliott, Fiona Wightman, Ajantha Solomon, et al.
PLoS Pathogens (2014) Vol. 10, Iss. 11, pp. e1004473-e1004473
Open Access | Times Cited: 483
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Søgaard, Mette E Graversen, Steffen Leth, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 9, pp. e1005142-e1005142
Open Access | Times Cited: 478
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Gregory M. Laird, C. Korin Bullen, Daniel I. S. Rosenbloom, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 5, pp. 1901-1912
Open Access | Times Cited: 375
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
Glen M. Chew, Tsuyoshi Fujita, Gabriela M. Webb, et al.
PLoS Pathogens (2016) Vol. 12, Iss. 1, pp. e1005349-e1005349
Open Access | Times Cited: 294
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
Jonathan Z. Li, Behzad Etemad, Hayat Ahmed, et al.
AIDS (2015), pp. 1-1
Open Access | Times Cited: 282
Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Nancie M. Archin, Julia Marsh Sung, Carolina Garrido, et al.
Nature Reviews Microbiology (2014) Vol. 12, Iss. 11, pp. 750-764
Open Access | Times Cited: 268
Target engagement and drug residence time can be observed in living cells with BRET
Matthew B. Robers, Melanie L. Dart, Carolyn C. Woodroofe, et al.
Nature Communications (2015) Vol. 6, Iss. 1
Open Access | Times Cited: 257
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
R. Brad Jones, Rachel W O’Connor, Stefanie Mueller, et al.
PLoS Pathogens (2014) Vol. 10, Iss. 8, pp. e1004287-e1004287
Open Access | Times Cited: 195
Towards an HIV-1 cure: measuring the latent reservoir
Katherine M. Bruner, Nina N. Hosmane, Robert F. Siliciano
Trends in Microbiology (2015) Vol. 23, Iss. 4, pp. 192-203
Open Access | Times Cited: 186
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations
Judith Grau-Expósito, Laura Luque-Ballesteros, Jordi Navarro, et al.
PLoS Pathogens (2019) Vol. 15, Iss. 8, pp. e1007991-e1007991
Open Access | Times Cited: 146
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Jesper Damsgaard Gunst, Marie H. Pahus, Míriam Rosás-Umbert, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2424-2435
Open Access | Times Cited: 72
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs
Yonggang Zhang, Chaoran Yin, Ting Zhang, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 154
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
R. Brad Jones, Stefanie Mueller, Rachel W O’Connor, et al.
PLoS Pathogens (2016) Vol. 12, Iss. 4, pp. e1005545-e1005545
Open Access | Times Cited: 152
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Angela Tsai, Alivelu Irrinki, Jasmine Kaur, et al.
Journal of Virology (2017) Vol. 91, Iss. 8
Open Access | Times Cited: 150
Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir
Biswajit Das, Curtis Dobrowolski, Benjamin G. Luttge, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 33
Open Access | Times Cited: 146
HIV “shock and kill” therapy: In need of revision
Erik Abner, Albert Jordan
Antiviral Research (2019) Vol. 166, pp. 19-34
Closed Access | Times Cited: 142
BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency
Lars Pache, Míriam Santos Dutra, Adam M. Spivak, et al.
Cell Host & Microbe (2015) Vol. 18, Iss. 3, pp. 345-353
Open Access | Times Cited: 132
Molecular mechanisms of HIV latency
Daniele C. Cary, Koh Fujinaga, B. Matija Peterlin
Journal of Clinical Investigation (2016) Vol. 126, Iss. 2, pp. 448-454
Open Access | Times Cited: 132
Epigenetic control of HIV-1 post integration latency: implications for therapy
Amit Kumar, Gilles Darcis, Carine Van Lint, et al.
Clinical Epigenetics (2015) Vol. 7, Iss. 1
Open Access | Times Cited: 104
Epigenomes as therapeutic targets
Christopher A. Hamm, Fabrício F. Costa
Pharmacology & Therapeutics (2015) Vol. 151, pp. 72-86
Closed Access | Times Cited: 103
HIV-1 Eradication: Early Trials (and Tribulations)
Adam M. Spivak, Vicente Planelles
Trends in Molecular Medicine (2015) Vol. 22, Iss. 1, pp. 10-27
Open Access | Times Cited: 102
The Effect of Latency Reversal Agents on Primary CD8 + T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
Victoria E. Walker-Sperling, Christopher W. Pohlmeyer, Patrick M. Tarwater, et al.
EBioMedicine (2016) Vol. 8, pp. 217-229
Open Access | Times Cited: 93
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
Derek D. Sloan, Chia‐Ying K. Lam, Alivelu Irrinki, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 11, pp. e1005233-e1005233
Open Access | Times Cited: 92
Reversal of Latency as Part of a Cure for HIV-1
Thomas A. Rasmussen, Martin Tolstrup, Ole S. Søgaard
Trends in Microbiology (2015) Vol. 24, Iss. 2, pp. 90-97
Closed Access | Times Cited: 91
Page 1 - Next Page

Scroll to top